SAN ANTONIO — Tamoxifen lowered overall and invasive ipsilateral recurrence among women with “good-risk” ductal carcinoma in situ who opted for breast conservation surgery without radiation.
Patients who received tamoxifen exhibited a 44% reduction in risk for any ipsilateral recurrence compared with those who did not receive the agent, findings presented at San Antonio Breast Cancer Symposium showed.
“Previously available data were conflicting about how much impact tamoxifen had on invasive DCIS recurrences among patients with favorable prognostic favors, so this